

## DAFTAR PUSTAKA

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 2004. *The Seven Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure*. 2004. *Arch intern Med*.

American Heart Association. 2000. *High Blood Pressure*.  
[Http://www.americanheart.org/Heart and Hypertension Guide/hbp.html-11k](http://www.americanheart.org/Heart%20and%20Hypertension%20Guide/hbp.html-11k).

Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. 1997. *The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure*. 1997. *Arch intern Med*.

Bustan MN. Hypertensive disease. Dalam; *Epidemiologi penyakit tidak menular*. PT Rineka Jakarta 1997.

Kaplan, N.M. 1998. *Primary Hypertension: Pathogenesis*. In: *Clinical Hypertension*, Kaplan NM, editor, 7 ed, chapter 3, p.41.

Weder, A.B. 1997. Pathogenesis of hypertension: Genetic and environmental factors. In: Hollenberg NK, *Hypertension: Mechanisms and Therapy. Atlas of heart disease*, Braunwald E, Chapter 1, p.1.

- World Health Organization. Management Guidelis. A mild Hypertension. Medicine Digest. June 1995.
- Boedhi Darmojo, R. Epidemiologi Hipertensi di Indonesia. Symposium Hipertensi, Surakarta 27 Februari 1991.
- Kaplan, N.M. 1983. *Hypertension. Prevalence, risks, and effect of therepy. Ann Intern Med.*
- Bauer, J. & Reams, G. 1995. The angiotensin II type 1 receptor antagonist. A new class of antihypertensive drugs. *Arch Intern Med.*
- Guyton AC, Hall JE, Lohmeier TE, Manning RD Jr, Pan Y. *Role of the kidney and volume controlin the pathogenesis of hypertension. Dalam: Robertson JIS, ed. Handbook of Hypertension: Clinical Aspects of Essential Hypertension.*
- Lund-Johansen P. *Central haemodinamics in essential hypertension at rest and during exercise: a 20 year follow up study. J Hypertens* 1989.